CodeBreaK 200 study: Intracranial efficacy of sotorasib
Patients with KRAS G12C-mutated advanced NSCLC often experience brain metastases, which can have a negative impact on their survival and quality of life. However, a recent global clinical trial called CodeBreaK 200 showed promising results for sotorasib, the first oral KRAS G12C inhibitor. Compared to intravenous docetaxel, sotorasib demonstrated improved progression-free survival, overall response rate, and a better toxicity profile and quality of life. Prof Dr Anne-Marie Dingemans from the Erasmus MC Cancer Institute in Rotterdam presented a poster at ASCO 2023 with the first data evaluating the intracranial efficacy of sotorasib versus docetaxel in the CodeBreaK 200 study.
With the educational support of:
